Medical lab partnership expanded: BHealthcare secures deals with three European labs for the delivery of 30 or more autonomous blood-drawing devices
BHealthCare, a pioneering MedTech company specializing in autonomous robotic solutions for peripheral vascular access, is making significant progress with its robotic medical technology, HEIVA. The device, designed to autonomously draw blood samples from patients, is set to revolutionize blood sample collection in Europe.
Current Status
HEIVA, an innovative autonomous device, is currently undergoing regulatory approvals in key markets. The company has announced supply agreements with three European medical biology laboratories for pre-orders of the device. As of now, HEIVA is in the registration process to obtain a CE mark and GCC approval for the European market. BHealthCare anticipates obtaining CE marking for HEIVA next year.
In clinical settings, HEIVA has already demonstrated safety and efficacy comparable to traditional venipuncture methods. The device is designed to improve efficiency, reduce discomfort, and increase accuracy in blood sample collection.
Future Plans
BHealthCare's vision for HEIVA extends beyond initial pilot markets. The company plans to expand HEIVA’s presence to broader healthcare facilities, diagnostics labs, and potentially even home healthcare services.
To support further development, regulatory processes, and market entry efforts, BHealthCare is currently engaged in fundraising activities. This includes seeking venture capital investments, partnerships, and strategic collaborations with healthcare providers or medical device companies.
Continued improvements are expected for HEIVA, with enhancements in AI algorithms, usability features, and integration with healthcare IT systems on the horizon.
For the most up-to-date detailed status or financial figures, it is recommended to check BHealthCare’s official announcements or recent press releases, as this information can change rapidly with new regulatory milestones and funding rounds. Since its founding in late 2016, BHealthCare has raised 13.5 million EUR (15M USD) in capital funds and grants.
As one of the first MedTech companies in Europe, and among only a handful in the world, capable of offering this robotic autonomous blood drawing technology, BHealthCare is poised to lead the way in the future of medical technology.
Digital health technology, such as BHealthCare's HEIVA, is poised to revolutionize patient care in Europe by automating blood sample collection. The innovative device is currently undergoing regulatory approvals in key markets and is already demonstrating safety and efficacy comparable to traditional methods.
BHealthCare's future plans include expanding HEIVA's presence to broader healthcare facilities, diagnostics labs, and potentially even home healthcare services. To facilitate this growth, they are currently engaged in fundraising activities, seeking venture capital investments, partnerships, and strategic collaborations.
The continual development of HEIVA is expected to include enhancements in AI algorithms, usability features, and integration with healthcare IT systems. This technology has the potential to significantly impact health-and-wellness, medical-conditions management, and even the business and finance sides of healthcare.
As a pioneer in autonomous robotic solutions for peripheral vascular access, BHealthCare is leading the way in the future of medical technology, leveraging science and technology to improve patient care and efficiency.
